Excyte was co-founded by Meng Qingwu and Yuan Qing'an, both of whom have returned from a renowned international pharmaceutical company. We have established a wholly-owned subsidiary in the United States, creating a Sino-US dual-wheel driven drug research and development center.
The company utilizes the information, technology, and talent advantages of both China and the United States to develop innovative bispecific antibodies for treating blood cancers, multiple myeloma, triple-negative breast cancer, etc. Many projects exhibit long-acting, low toxicity, and high productivity, and are all updated products of international benchmark products.